196 related articles for article (PubMed ID: 30408048)
1. AFLP-AFLP in silico-NGS approach reveals polymorphisms in repetitive elements in the malignant genome.
Koblihova J; Srutova K; Krutska M; Klamova H; Machova Polakova K
PLoS One; 2018; 13(11):e0206620. PubMed ID: 30408048
[TBL] [Abstract][Full Text] [Related]
2. Next-generation sequencing for sensitive detection of BCR-ABL1 mutations relevant to tyrosine kinase inhibitor choice in imatinib-resistant patients.
Soverini S; De Benedittis C; Polakova KM; Linhartova J; Castagnetti F; Gugliotta G; Papayannidis C; Mancini M; Klamova H; Salvucci M; Crugnola M; Iurlo A; Albano F; Russo D; Rosti G; Cavo M; Baccarani M; Martinelli G
Oncotarget; 2016 Apr; 7(16):21982-90. PubMed ID: 26980736
[TBL] [Abstract][Full Text] [Related]
3. In silico fingerprinting (ISIF): a user-friendly in silico AFLP program.
Paris M; Després L
Methods Mol Biol; 2012; 888():55-64. PubMed ID: 22665275
[TBL] [Abstract][Full Text] [Related]
4. Two methods to easily obtain nucleotide sequences from AFLP loci of interest.
Paris M; Meyer CL; Blassiau C; Coissac E; Taberlet P; Després L
Methods Mol Biol; 2012; 888():91-108. PubMed ID: 22665277
[TBL] [Abstract][Full Text] [Related]
5. Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment.
Jaruskova M; Curik N; Hercog R; Polivkova V; Motlova E; Benes V; Klamova H; Pecherkova P; Belohlavkova P; Vrbacky F; Machova Polakova K
J Exp Clin Cancer Res; 2017 Apr; 36(1):55. PubMed ID: 28420426
[TBL] [Abstract][Full Text] [Related]
6. Ultra-deep sequencing leads to earlier and more sensitive detection of the tyrosine kinase inhibitor resistance mutation T315I in chronic myeloid leukemia.
Baer C; Kern W; Koch S; Nadarajah N; Schindela S; Meggendorfer M; Haferlach C; Haferlach T
Haematologica; 2016 Jul; 101(7):830-8. PubMed ID: 27102501
[TBL] [Abstract][Full Text] [Related]
7. Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.
Khalil SH; Abu-Amero KK; Al Mohareb F; Chaudhri NA
Genet Test Mol Biomarkers; 2010 Feb; 14(1):67-74. PubMed ID: 19943786
[TBL] [Abstract][Full Text] [Related]
8. hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia.
Ben Hassine I; Gharbi H; Soltani I; Teber M; Farrah A; Ben Hadj Othman H; Amouri H; Bellaaj H; Lakhal RB; Romdhane NB; Abbes S; Menif S
Cancer Chemother Pharmacol; 2017 Apr; 79(4):737-745. PubMed ID: 28286932
[TBL] [Abstract][Full Text] [Related]
9. [MET/ERK and MET/JNK Pathway Activation Is Involved in BCR-ABL Inhibitor-resistance in Chronic Myeloid Leukemia].
Tsubaki M
Yakugaku Zasshi; 2018; 138(12):1461-1466. PubMed ID: 30504658
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia.
Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3317-3320. PubMed ID: 30583336
[TBL] [Abstract][Full Text] [Related]
11. Amplified fragment length polymorphism: an adept technique for genome mapping, genetic differentiation, and intraspecific variation in protozoan parasites.
Kumar A; Misra P; Dube A
Parasitol Res; 2013 Feb; 112(2):457-66. PubMed ID: 23254590
[TBL] [Abstract][Full Text] [Related]
12. In chronic myeloid leukemia patients on second-line tyrosine kinase inhibitor therapy, deep sequencing of BCR-ABL1 at the time of warning may allow sensitive detection of emerging drug-resistant mutants.
Soverini S; De Benedittis C; Castagnetti F; Gugliotta G; Mancini M; Bavaro L; Machova Polakova K; Linhartova J; Iurlo A; Russo D; Pane F; Saglio G; Rosti G; Cavo M; Baccarani M; Martinelli G
BMC Cancer; 2016 Aug; 16():572. PubMed ID: 27485109
[TBL] [Abstract][Full Text] [Related]
13. Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.
Casado LF; García-Gutiérrez JV; Massagué I; Giraldo P; Pérez-Encinas M; de Paz R; Martínez-López J; Bautista G; Osorio S; Requena MJ; Palomera L; Peñarrubia MJ; Calle C; Hernández-Rivas JÁ; Burgaleta C; Maestro B; García-Ormeña N; Steegmann JL
Cancer Med; 2015 Jul; 4(7):995-1002. PubMed ID: 25756742
[TBL] [Abstract][Full Text] [Related]
14. PDGFRα promoter polymorphisms and expression patterns influence risk of development of imatinib-induced thrombocytopenia in chronic myeloid leukemia: A study from India.
Guru SA; Mir R; Bhat M; Najar I; Zuberi M; Sumi M; Masroor M; Gupta N; Saxena A
Tumour Biol; 2017 Oct; 39(10):1010428317713857. PubMed ID: 29019285
[TBL] [Abstract][Full Text] [Related]
15. Identifying patterns of DNA for tumor diagnosis using capillary electrophoresis-amplified fragment length polymorphism (CE-AFLP) screening.
Wong KY; Chuan YC; Aggarwal A; Tham L; Kong WM; Tan P
J Bioinform Comput Biol; 2004 Sep; 2(3):569-87. PubMed ID: 15359427
[TBL] [Abstract][Full Text] [Related]
16. ATG-anchored AFLP (ATG-AFLP) analysis in cotton.
Lu Y; Curtiss J; Miranda D; Hughs E; Zhang J
Plant Cell Rep; 2008 Oct; 27(10):1645-53. PubMed ID: 18584177
[TBL] [Abstract][Full Text] [Related]
17. Performance comparison of two reduced-representation based genome-wide marker-discovery strategies in a multi-taxon phylogeographic framework.
Kirschner P; Arthofer W; Pfeifenberger S; Záveská E; Schönswetter P; ; Steiner FM; Schlick-Steiner BC
Sci Rep; 2021 Feb; 11(1):3978. PubMed ID: 33597550
[TBL] [Abstract][Full Text] [Related]
18. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
[TBL] [Abstract][Full Text] [Related]
19. Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML).
Desterke C; Voldoire M; Bonnet ML; Sorel N; Pagliaro S; Rahban H; Bennaceur-Griscelli A; Cayssials E; Chomel JC; Turhan AG
Exp Hematol; 2018 Aug; 64():71-83.e8. PubMed ID: 29733872
[TBL] [Abstract][Full Text] [Related]
20. A repetitive sequence assembler based on next-generation sequencing.
Lian S; Tu Y; Wang Y; Chen X; Wang L
Genet Mol Res; 2016 Jul; 15(3):. PubMed ID: 27525861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
